## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Bendele et al.

Serial No.: Not Yet Received

Group Art Unit No.: 1646

Filed:

July 17, 2001

Examiner: E. O'Hara

For:

COMBINATION THERAPY USING A THE BINDING

PROTEIN FOR TREATING TNF-MEDIATED

**DISEASES** 

Docket No.: A-430F

## PRELIMINARY AMENDMENT

**Assistant Commissioner for Patents** Washington, D.C. 20231

Sir:

Please amend the referenced application as follows:

In the Specification

At page 1, line 3, insert the following paragraph:

This application is a divisional of application Serial No. 09/326,394 filed June 4, 1999, which is a continuation of PCT/US97/22733, filed December 8, 1997, which claims benefit to U.S. Provisional Serial No. 60/032,587, filed December 6, 1996, U.S. Provisional Serial No. 60/036,355, filed January 23, 1997, U.S. Provisional Serial No. 60/039,315, filed February 7, 1997 and U.S. Provisional Serial No. 60/052,023, filed July 9, 1997, all of which are hereby incorporated by reference.

## In the Claims

Please cancel claims 2-26 and insert the following new claims:

27. The method of treatment of an acute or chronic inflammatory disease of Claim 1, which comprises administering a TNK vinding protein in combination with the prior, concurrent, or post-administration of a COX2 inhibitor.

The method of treatment according to claim 27, wherein the COX2 inhibitor is celecoxib. 28.

## **EXPRESS MAIL CERTIFICATE**

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express